In a private-label project, manufacture is outsourced, but regulatory responsibility, ownership of documentation and rights to use the formula must be clear before launch.
The contract manufacturer is not automatically the Responsible Person
A manufacturer may develop and produce the cosmetic, but the Responsible Person is determined by the Regulation, the supply model and any written designation. A brand should not assume that the supplier automatically takes every regulatory obligation.
The label and CPNP must identify the person genuinely appointed. The agreement should state who approves the formula, label, claims, changes and market release.
Access to formula and documentation
The Responsible Person and safety assessor need access to the information required for the CPSR and PIF. Formula confidentiality can be protected contractually, but it cannot prevent lawful assessment and authority access.
Define who owns the CPSR, PIF, study reports and artwork and whether the brand may use them after changing manufacturer or Responsible Person. Unclear ownership can block continuity.
Practical checkpoint
Every conclusion should be linked to the exact formula, document and market-material version. This makes it possible to demonstrate which evidence supported the regulatory decision.
GMP, specifications and batch release
The contract manufacturer should operate under GMP and control raw materials, processes, batches, deviations and changes. The brand needs to understand which records are available and how non-conformities are managed.
Finished-product specifications, release criteria and retained-sample responsibilities should be agreed. Commercial pressure must not override a professional decision that a batch is unacceptable.
Labelling, claims and markets
A supplier’s standard text may not suit every Member State or sales channel. The brand needs to ensure that product name, claims, languages and marketing communication match the product and market.
Changing a claim or artwork may require renewed review of evidence, the CPSR, PIF and CPNP record. The approval workflow should include both marketing and regulatory input.
Supplier changes and business continuity
The agreement should require notification of changes in raw materials, suppliers, process, manufacturing site, packaging or specification. No change should be implemented before safety and regulatory impact are assessed.
An exit plan should ensure access to documentation, transition of CPNP records where possible, label changes and availability of data for complaints and undesirable effects.
Frequently asked questions
Is the manufacturer’s CPSR sufficient for my brand?
It must cover the exact formula, product name, use, packaging and variant of your branded product and form part of an accessible PIF.
Can the same formula be sold under several brands?
Potentially, but identity, labels, claims, Responsible Person and CPNP records must be correctly managed.
Who approves a formula change?
The process and responsibilities should be agreed, with safety and regulatory impact assessed before implementation.
Official sources and further reading
This article is for general information and does not replace an assessment of the specific product, formula and supply chain. Legislation and guidance may change after publication.